Gilead Sciences EVP Kevin Young Sells 100,000 Shares (GILD)
Gilead Sciences (NASDAQ:GILD) EVP Kevin Young sold 100,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $62.88, for a total value of $6,288,000.00. Following the transaction, the executive vice president now directly owns 161,840 shares of the company’s stock, valued at approximately $10,176,499. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
GILD has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Gilead Sciences (NASDAQ:GILD) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $66.00 price target on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Gilead Sciences (NASDAQ:GILD) in a research note to investors on Friday, September 20th. Finally, analysts at Ameriprise Financial initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note to investors on Thursday, September 19th. They set a “buy” rating on the stock.
Six research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $67.57.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 1.61% during mid-day trading on Wednesday, hitting $61.73. 5,358,277 shares of the company’s stock traded hands. Gilead Sciences has a 1-year low of $32.07 and a 1-year high of $64.74. The stock’s 50-day moving average is $60.78 and its 200-day moving average is $54.76. The company has a market cap of $94.485 billion and a price-to-earnings ratio of 35.11.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, July 25th. The company reported $0.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.50. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the prior year, the company posted $0.99 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $1.97 earnings per share for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.